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Abstract Gastric cancer (GC) is a second most common
cause of cancer-related death and represents an inﬂamma-
tion-driven malignancy. It has been suggested that inter-
leukin 6 (IL-6) and C-reactive protein (CRP) play a
potential role in the growth and progression of GC. The
aim of the present study was to compare clinical signiﬁ-
cance of IL-6 and CRP with classic tumor markers—car-
cinoembryonic antigen (CEA) and carbohydrate antigen
(CA 19-9) in GC patients. The study included 92 patients
with GC and 70 healthy subjects. The serum concentrations
of IL-6, CEA and CA 19-9 were determined using immu-
noenzyme assays, whereas CRP using immunoturbidimet-
ric method. We deﬁned the diagnostic criteria and
prognostic value for proteins tested. In GC patients, the
serum concentrations of all the proteins tested were sig-
niﬁcantly higher than in healthy subjects. The IL-6, CEA
and CA 19-9 levels correlated with nodal metastases, while
CRP with tumor stage, gastric wall invasion, presence of
nodal and distant metastases. Diagnostic sensitivity of IL-6
was higher (85%) than those of other markers (CRP 66%,
CA 19-9 34%, CEA 22%) and increased in combined use
with CRP or CEA (88%). The area under ROC curve for
IL-6 was larger than those of CRP and classic tumor
markers (CEA and CA 19-9). None of the proteins tested
was independent prognostic factor for the survival of GC
patients. Our ﬁndings indicate better usefulness of serum
proinﬂammatory proteins—IL-6 and CRP than classic
tumor markers—CEA and CA 19-9 in the diagnosis of GC.
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Introduction
Gastric cancer (GC) remains a second most common cause
of cancer-related death worldwide and the predicted inci-
dence for 2010 is over 1 million [1, 2]. Several factors are
suspected to play a role in the development of GC,
including effects of diet, intake of smoked, exogenous
chemicals, genetic factors or infectious agents [2, 3].
Clinical and epidemiological studies have shown the link
between gastric cancer and chronic inﬂammation, thus
pathogenesis of GC represents an inﬂammation-driven
malignancy [2, 4]. The potential signiﬁcance of interleukin
6 (IL-6) and C-reactive protein (CRP) has been suggested
in the growth and progression of many malignancies,
including GC [5, 6].
IL-6 is a pleiotropic inﬂammatory cytokine that plays
conﬂicting role into tumor cells [7–9]. It may promote the
killing of cancer cells by the stimulation of antitumor
activity of macrophages and prevents apoptosis of neutro-
phils [7, 8]. However, IL-6 may be also produced by tumor
cells, including GC cell lines [7, 10]. It has been suggested
that the IL-6 pathway is one of the mechanism that link
inﬂammation and angiogenesis to malignancy [5]. This
cytokine is able to induce the expression of vascular
endothelial growth factor (VEGF) [11]. In addition, IL-6
activates the Rho protein, which is associated with cell–cell
adhesion and invasion in cancer [12]. Some authors have
shown the expression of this cytokine and its receptor in
GC tissue [10, 13, 14]. These ﬁndings suggested that IL-6
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gastric carcinomas and play a crucial role in the patho-
genesis of GC [10, 13–15]. C-reactive protein is produced
by hepatocytes as a response to inﬂammatory cytokines,
such as IL-6, during tissues damage induced by infection,
trauma or cancer [9]. Some authors have suggested that
malignancy induced CRP production in hepatocytes [16].
Recently, CRP has been associated with the progression of
disease in many types of cancers, including GC [5].
Increased concentrations of IL-6 and CRP were detected in
the blood of patients with colorectal [17], lung [18] and
gastric cancer [3, 5, 19, 20]. It has been shown that IL-6
and CRP levels correlated with clinicopathological features
of GC, such as tumor stage, depth of tumor invasion and
the presence of lymph node metastasis [3, 5, 7, 19, 20].
Some authors have also suggested the potential signiﬁ-
cance of IL-6 and CRP as prognostic factors for the sur-
vival of GC patients [5, 7, 15, 19]. However, according to
our knowledge, this is the ﬁrst study assessing diagnostic
criteria for IL-6 and CRP in the sera of GC patients,
especially in comparison with classic tumor markers—
carcinoembryonic antigen (CEA) and carbohydrate antigen
(CA 19-9).
Therefore, the aim of the present study was to compare
the clinical signiﬁcance of serum IL-6 and CRP with
classic tumor markers (CEA and CA 19-9) in the diagnosis
of GC patients based on the diagnostic criteria, such as
diagnostic sensitivity and speciﬁcity, positive and negative
predictive values as well as ROC curve. Moreover, we
assessed the concentrations of IL-6, CRP and classic tumor
markers in the sera of GC patients in relation to clinico-
pathological features of cancer, including tumor stage,
depth of tumor invasion, the presence of lymph node and
distant metastases as well as resectability of tumor and
patients’ survival.
Materials and methods
Patients
The study included 92 GC patients (27 women and 65 men,
aged 28–84 years) diagnosed by the Oncology Group and
operated on by the Second General Medicine Department of
the Medical University of Białystok. The control group
comprised 70 healthy volunteers (53 women and 15 men,
aged 20–69 years). The microscopic examination of mate-
rial obtained during biopsy and/or surgery was used in the
clinical diagnosis of GC patients. Seventy-two GC patients
underwent surgical tumor resection, while 20 patients
had nonresectable tumors. The staging of cancer was
based on a routine histopathological analysis and clinical
assessment, according to TNM (tumor-nodulus-metastases)
classiﬁcation. Tumors were classiﬁed proposed by the 5th
International Union Against Cancer (UICC) [21].
For statistical analysis, GC patients were divided into
three groups: 19 cancer patients in stage I ? II, 27 patients
in stage III, and 46 patients in stage IV. They were also
subdivided into: three groups depending on gastric wall
invasion (T1 ? T2, T3 and T4), four groups depending on
nodal involvement (N0, N1, N2 and N3) and two groups
depending on the presence of distant metastasis (M0 and
M1). Thirty-six patients died of GC, whereas 50 patients
survived. The number of patients in the analyzed subgroups
is shown in Table 1. The study was approved by the Local
Table 1 Characteristic of gastric cancer patients
Tested group Number of patients
Gastric cancer patients 92
Gender
Female 27
Male 65
Age
C65 years 45
\65 years 47
Tumor stage
11 2
27
1 ? 21 9
32 7
44 6
Tumor size
T1 7
T2 8
T1 ? T2 15
T3 41
T4 36
Nodal metastases
N0 19
N1 12
N2 22
N3 39
Distant metastases
M0 53
M1 39
Resectability of tumor
Resectable 72
Nonresectable 20
Survival of patients
Died 36
Alive 50
Data not available 6
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123Ethics Committee, and all the patients gave informed
consent.
Biochemical analyses
Blood samples from all the patients were drawn before
treatment (Sarstedt, Nu ¨mbrecht, Germany), and then sera
were separated within 1 h after blood collection and stored
at -80C until analysis.
Serum IL-6 concentrations were measured using an
enzyme-linked immunosorbent assay kits (ELISA) (R&D
Systems, Abingdon, UK) according to the manufacturer’s
instructions. The intra-assay coefﬁcient of variation (CV%)
is reported by the manufacturer to be 4.2% at a mean
concentration of 16.8 pg/mL with SD = 0.7 pg/mL. Con-
centrations of CRP in the sera were determined using an
immunoturbidimetric Protiline
 CRP assay kits (bio-
Merieux, Lyon, France) in accordance with the manufac-
turer’s instructions. The intra-assay CV% reported by
the manufacturer is 2.49% at a mean concentration of
10 mg/L.
Serum concentrations of CEA and CA 19-9 in the
patients and healthy controls were measured using a
microparticle enzyme immunoassay kits (MEIA) (Abbott,
Chicago, IL, USA). The intra-assay CV% for CEA as
reported by the manufacturer of the assay kits is 4.9% at a
mean concentration of 2.2 ng/mL with SD of 0.11 ng/mL,
and the intra-assay CV% for CA 19-9 is 4.7% at a mean
concentration of 38.2 U/mL with SD = 1.80 U/mL.
The reference cut-off values for CEA (4.0 ng/mL) and
CA 19-9 (30.0 U/mL) (the 95th percentile) were estab-
lished previously in our department [17]. The cut-off val-
ues for IL-6 (2.46 pg/mL) and CRP (5.2 mg/L) correspond
to the highest accuracy (minimal false-negative and false-
positive results).
Statistical analysis
The values of IL-6, CRP, CEA and CA 19-9 levels did not
follow a normal distribution in preliminary statistical
analysis (v
2-test). The comparisons between two groups
were performed by the Mann–Whitney U-test and for three
groups or more, the one-way ANOVA Kruskal–Wallis test
was used. Data are presented as the median and range. The
differences were considered statically signiﬁcant when
P\0.05. The Kaplan and Meier method was used for the
calculation of the survival curves. The log-rank test for
univariate analyses of survival and the Cox proportional
hazards model for multivariate analyses were employed. In
addition, we calculated the area under the receiver oper-
ating characteristic (ROC) curve (AUC) for the IL-6, CRP
and classic tumor markers. Statistical analysis was per-
formed using the STATISTICA 5.1 PL program (StatSoft
Inc., Tulsa, OK, USA). Diagnostic criteria were calculated
using MedCalc statistical software (Mariakerke, Belgium)
and Microsoft Ofﬁce Excel.
Results
Tables 2 and 3 present the median and range of serum
concentrations of IL-6, CRP and classic tumor markers
(CEA and CA 19-9) in GC patients and in healthy subjects
(control group). In GC patients, the concentrations of all
the proteins tested were found to be statistically higher
when compared with healthy subjects (P\0.001). The
serum concentrations of IL-6, CRP and tumor markers in
GC patients increased with tumor stage and were the
highest in patients with stage IV, although statistically
signiﬁcant differences were found between stage IV and II
for CRP (P = 0.025) (Table 2) and between stage IV, III
and II for CA 19-9 (0.028) (Table 3).
If we consider the concentrations of IL-6, CRP and
classic tumor markers in relation to clinicopathological
variables of tumor, such as gastric wall invasion (T factor),
the serum levels of all the proteins measured are highest in
patients in T4 subgroup. The differences between T1?2,
T3 and T4 subgroups are signiﬁcant for serum CRP levels
and between T1?2 and T4 for CA 19-9. Serum levels of all
the proteins tested varied according to nodal metastases (N
factor) and were the highest in the N3 subgroup. The CRP
and CEA concentrations were signiﬁcantly higher in N3
subgroup than in N0 and N2 patients (respectively,
P = 0.020 and P = 0.046), the IL-6 levels were signiﬁ-
cantly higher in N3 patients when compared with N2
tumors (0.040), whereas CA 19-9 concentrations were
signiﬁcantly different in N3 and N1 subgroups than in N0
patients (0.001). The serum concentrations of all the pro-
teins tested correlated with the presence of distant metas-
tasis (M factor) and were higher in M1 subgroup when
compared with patients without distant metastasis. How-
ever, the differences were found to be signiﬁcant only for
CRP levels (0.026). Moreover, serum levels of CRP, IL-6
and CA 19-9 were higher in patients with nonresectable
tumors in comparison with those with the resectable ones,
although these differences were not signiﬁcant.
The relationship between survival of GC patients and
serum concentrations of proteins tested was assessed using
the Kaplan–Meier method. The univariate log-rank analy-
sis showed that the tumor stage (P = 0.001), tumor size
(P = 0.003), the presence of nodal (P = 0.001) and distant
metastases (P = 0.001), tumor resectability (P = 0.001) as
well as the serum levels of CEA and CA 19-9 (p = 0.005)
were the signiﬁcant factors affecting overall survival
(Table 4). Multivariate regression analysis with the Cox’s
proportional hazards model revealed that only tumor stage
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presence of distant metastasis (P = 0.019) were indepen-
dent prognostic factors for the survival of GC patients.
The percentage of increased concentrations (diagnostic
sensitivity) of proteins tested is presented in Fig. 1. The
diagnostic sensitivity of IL-6 (85%) was higher than those
of CRP (66%) and much higher than classic tumor mark-
ers—CEA (22%) and CA 19-9 (34%). Moreover, the fre-
quency of increased concentrations was the highest for the
combination of IL-6 with CRP or IL-6 with CEA levels
(88%) and improved the diagnostic sensitivity of tumor
markers—CEA with CA 19-9 (43%) (Fig. 1). The diag-
nostic speciﬁcity for CRP levels (91%) was slightly lower
than for classic tumor markers (100%), similarly as posi-
tive predictive value. However, negative predictive value
was higher for IL-6 (80%) when compared with CRP
(67%), CA 19-9 (53%) and CEA (49%). The highest
negative predictive value was observed for combined use
of IL-6 with CRP (83%) or CEA (84%).
The area under the ROC curve (AUC) indicates the
clinical usefulness of the proteins tested. The IL-6 area
under ROC curve (0.8984) was higher than AUC for CRP
(0.8075) and much higher than for CEA (0.7737) and CA
19-9 (0.7619) in the diagnosis of GC patients (Fig. 2).
Discussion
Gastric cancer (GC) is the fourth most common cancer and
the second cause of cancer death in the world [22]. It shows
extensive tumor invasion and early spread to metastasis
sites [23]. Several serum tumor markers have been used in
Table 2 Serum concentrations of CRP and IL-6 in gastric cancer patients
N CRP (mg/L) IL-6 (pg/mL)
Median Range P Median Range P
Gastric cancer patients 92 11.1
a 1.4 238.7 \0.001 8.04
a 0.00 201.97 \0.001
Control group 70 5.0 0.1 8.9 1.32 0.00 26.71
Tumor stage
II 19 5.0
a 1.7 59.3 0.025 4.69
a 0.00 46.24 0.451
III 27 10.4
a 1.7 145.9 6.92
a 1.27 69.20
IV 46 15.3
a,b 1.4 238.7 9.09
a 1.12 201.97
Gastric wall invasion
T1 ? T2 15 5.0
a,c 1.7 43.5 0.005 5.13
a 0.40 46.24 0.283
T3 41 10.2
a,c 1.4 145.9 5.88
a 0.00 69.20
T4 36 19.2
a 1.9 238.7 9.53
a 1.42 201.97
Nodal metastases
N0 19 8.5
a 1.7 59.3 0.020 5.13
a 0.00 46.24 0.040
N1 12 7.9
a 1.7 60.4 5.07
a 1.44 69.20
N2 22 7.3
a 3.0 55.5 4.54
a 1.27 45.77
N3 39 16.8
a,d,e 1.4 238.7 11.26
a,e 2.01 201.97
Distant metastases
M0 53 7.8
a 1.7 145.9 0.026 5.44
a 0.00 69.20 0.227
M1 39 16.1
a,f 1.4 238.7 9.31
a 1.12 201.97
Resectability of tumor
Resectable 72 10.3
a 1.4 238.7 0.134 6.7
a 0.00 93.90 0.339
Nonresectable 20 17.9
a 1.9 90.1 9.75
a 2.01 201.97
Survival of patients
Alive 50 10.3
a 1.7 145.9 0.187 5.37
a 0.00 69.20 0.360
Died 36 12.2
a 1.4 238.7 9.09
a 1.12 93.90
a Statistically signiﬁcant compared to control group
b Statistically signiﬁcant compared to stage II
c Statistically signiﬁcant compared to T4 subgroup
d Statistically signiﬁcant compared to N0 subgroup
e Statistically signiﬁcant compared to N2 subgroup
f Statistically signiﬁcant compared to M0 subgroup
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demonstrated that increased levels of classic tumor mark-
ers, such as CEA and CA 19-9 correlated with clinico-
pathological features of GC [3, 19, 24, 25]. However,
sensitivity of classic tumor markers has not proven satis-
factory. Therefore, novel biochemical markers are neces-
sary in the diagnosis of GC patients.
In the present study, we assessed concentrations of the
proinﬂammatory cytokine—IL-6 and acute phase protein
(CRP) in the sera of GC patients and compared them with
classic tumor markers (CEA and CA 19-9). We demon-
strated that the serum levels of IL-6 and CRP as well as
classic tumor markers were signiﬁcantly higher in the GC
patients when compared with healthy subjects. Our ﬁnd-
ings are in agreement with a report of other authors [3, 19],
who showed signiﬁcantly higher concentrations of IL-6 and
CRP in GC patients in comparison with healthy subjects. In
the present paper, the levels of IL-6, CRP and classic tumor
markers increased with tumor stage, although statistically
signiﬁcant differences were found only for CRP and CA
19-9. These ﬁndings are in line with a study of Kim et al.
[5], who found that serum levels of CRP signiﬁcantly
correlated with stage of GC. However, the authors also
indicated the signiﬁcant association between serum IL-6
concentrations and TNM stage [5, 19]. The opposite results
were shown in a study of Ilhan et al. [3], who failed to
establish any signiﬁcant differences between serum CRP
levels and tumor stage.
In addition, in the current study, serum concentrations of
IL-6, CRP and CA 19-9 increased with the gastric wall
invasion (T factor). The differences were signiﬁcant only
for CRP and CA 19-9. Similar results were obtained by
Table 3 Serum concentrations of classic tumor markers in gastric cancer patients
N CEA (ng/mL) CA 19-9 (U/mL)
Median Range P Median Range P
Gastric cancer patients 92 1.75
a 0.10 620.00 \0.001 10.23
a 0.00 50000.00 \0.001
Control group 70 0.70 0.00 3.9 2.00 0.00 24.01
Tumor stage
II 19 1.79
a 0.40 6.90 0.286 5.10
a 0.00 54.23 0.028
III 27 1.20
a 0.30 120.3 11.75
a,b 0.00 1200.00
IV 46 1.95
a 0.10 620.0 17.91
a,b 0.00 50000.00
Gastric wall invasion
T1 ? T2 15 1.79
a 0.40 11.89 0.448 5.75
c 0.00 54.23 0.081
T3 41 1.49
a 0.10 120.30 10.06
a 0.00 10900
T4 36 1.80
a 0.50 620.00 22.23
a 0.00 50000
Nodal metastases
N0 19 1.40
a 0.10 6.90 0.046 2.33 0.00 24.17 0.001
N1 12 1.16
a 0.56 40.59 13.89
a,d 1.27 723.22
N2 22 1.22
a 0.30 82.20 8.91
a 0.00 3262.00
N3 39 2.30
a,d,e 0.61 620.00 31.96
a,d 0.00 50000.00
Distant metastases
M0 53 1.49
a 0.30 120.30 0.155 9.07
a 0.00 1200.00 0.527
M1 39 2.00
a 0.10 620.00 15.69
a 0.00 50000.00
Resectability of tumor
Resectable 72 1.80
a 0.10 620.00 0.877 8.84
a 0.00 50000.00 0.147
Nonresectable 20 1.50
a 0.61 25.49 28.18
a 0.00 2844.00
Survival of patients
Alive 50 1.45
a 0.1 82.2 0.274 7.87
a 0.00 1200.00 0.082
Died 36 1.84
a 0.60 620.00 31.94
a 0.00 50000.00
a Statistically signiﬁcant compared to control group
b Statistically signiﬁcant compared to stage II
c Statistically signiﬁcant compared to T4 subgroup
d Statistically signiﬁcant compared to N0 subgroup
e Statistically signiﬁcant compared to N2 subgroup
f Statistically signiﬁcant compared to M0 subgroup
Clin Exp Med (2011) 11:89–96 93
123Kim et al. [5]; however, the authors also found the sig-
niﬁcant correlations between serum IL-6 levels and tumor
size. It has been suggested that in GC patients serum IL-6
and CRP may reveal the degree of damage of gastric wall
caused by ulcerative reaction of the tumor.
Serum levels of all the proteins tested varied according
to nodal metastases (N factor) and the CRP, IL-6 and CEA
concentrations were correlated with the presence of lymph
node metastasis. Our results are in agreement with ﬁndings
of Kim et al. [5], who revealed signiﬁcant differences in
lymph node metastasis and serum concentrations of CRP as
well as IL-6. Opposite ﬁndings were established by
Ikeguchi et al. [19], who found no signiﬁcant correlation
between serum IL-6 level and lymph node metastasis in
GC patients. Cancer invasion begins with inﬂammation
around the tumor cells [5]; therefore, CRP and IL-6 levels
might be higher in the sera of patients with invasive cancer
than those in noninvasive tumors. In addition, in the
present paper, the serum concentrations of all the proteins
tested correlated with the presence of distant metastasis (M
factor); however, the differences between M0 and M1
subgroups were found to be signiﬁcant only for CRP levels.
Opposite to our paper, the study of Thong-Ngam et al. [26]
have indicated that the IL-6 levels in GC patients with
distant metastasis were signiﬁcantly higher than in those
without metastasis. These ﬁndings have been attributed to a
host mechanism, including IL-6 autocrine and paracrine
pathway [5, 10, 13, 14]. IL-6 released from leukocytes
is able to activate the production of IL-6 by tumor cells
with the IL-6 receptor as well as stimulated stromal
cells promoted the secretion of molecules, such as VEGF
[3, 11, 27]. It has been proven that when concentrations of
IL-6 increased, CRP levels also increased, thus CRP has
Table 4 Results of Cox’s univariate analysis in gastric cancer
patients
Odds ratio P value
Tumor stage 0.001
a
TNM III versus TNM II 1.812 0.419
TNM IV versus TNM II 7.827 0.001
a
Tumor size (T factor) 0.003
a
T3 versus 2 1.456 0.529
T4 versus 2 4.393 0.008
a
N 0.001
a
N1 versus N0 0.776 0.826
N2 versus N0 2.855 0.131
N3 versus N0 8.437 0.001
a
M 7.615 0.001
a
Resectability 0.203 0.001
a
CEA 1.008 0.005
a
CA19-9 1.000 0.005
a
CRP 1.008 0.061
IL-6 1.013 0.238
a Statistically signiﬁcant when P\0.05
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Fig. 1 Percentage of increased concentrations (diagnostic sensitivity) of IL-6, CRP and tumor markers in gastric cancer patients
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123generally been connected with IL-6 and indirectly with
cancer progression [5].
Moreover, we revealed that the concentrations of IL-6,
CRP and CA 19-9 were signiﬁcantly higher in patients with
nonresectable tumor in comparison with the resectable
cancer group. Similar results were observed previously in
patients with colorectal cancer (CRC), although the dif-
ferences in IL-6 and CRP concentrations between the
group of patients with resectable tumor and subjects with
nonresectable CRC were statistically signiﬁcant [17].
We observed that the concentrations of IL-6, CRP and
classic tumor markers were higher in the sera of patients
who died of GC when compared with patients who sur-
vived. In agreement with present study, previously we
indicated the higher concentrations of both proinﬂamma-
tory proteins in patients who died because of CRC in
comparison with those who survived and these differences
were signiﬁcant [17]. We also assessed the relationship
between the survival of GC patients and the serum con-
centrations of the proteins tested using the Kaplan–Meier
method, although we did not detect any tendency that
would point to IL-6 and CRP as prognostic factors for GC
patients’ survival. Our observations are in the line with the
ﬁndings of Wu et al. [7], who indicated that serum levels of
IL-6 correlated with patients’ survival, but not as an
independent prognostic factor. Similarly, Ikeguchi et al.
[19] revealed that even though there was a signiﬁcant
difference in survival between patients with high levels of
serum IL-6 and those with low levels, serum IL-6 con-
centrations were not independent on tumor stage.
In the present study, we evaluated the diagnostic criteria,
such as the diagnostic sensitivity and speciﬁcity, positive
and negative predictive value as well as ROC curve for all
proteins tested. The percentage of increased concentrations
and negative predictive value of IL-6 was higher than those
of CRP and classic tumor markers and increased for the
combined use of IL-6 with CRP or CEA. The diagnostic
speciﬁcity for CRP levels was slightly lower than for classic
tumor markers, similarly as positive predictive value. The
percentage of increased concentrations of IL-6 (85%)
established in current paper was higher to those obtained
in previous studies, where we assessed the diagnostic
sensitivity of other biomarkers in GC patients, including
matrix metalloproteinase 9 (MMP-9) (60%) and its tissue
inhibitor (TIMP-1) (78%) as well as hematopoietic growth
factors (HGFs), such as granulocyte colony-stimulating
factor (G-CSF) (36%), granulocyte macrophage colony-
stimulating factor (GM-CSF) (29%), stem cell factor (SCF)
(19%) and macrophage colony-stimulating factor (M-CSF)
(10%) [24, 25]. However, the diagnostic speciﬁcity for CRP
(91%) was slightly lower than for M-CSF (95%), SCF
(94%) and G-CSF (92%), but higher than for GM-CSF
(82%) [25].
In addition, we showed that the IL-6 area under ROC
curve was higher than AUC for CRP and both classic
tumor markers. Current results of AUC for all proteins
tested are similar to those obtained in our previous study
concerning diagnostic usefulness of IL-6, CRP and classic
tumor markers in CRC patients [17] where we also showed
that AUC for IL-6 (0.8984) was higher than for CRP, CA
19-9 and CEA. Moreover, in the present study, the area
under ROC curve of IL-6 and CRP was higher than those
of other biomarkers of GC from our previous study, such
as: G-CSF (0.77), GM-CSF (0.70), SCF (0.62), M-CSF
(0.53) as well as MMP-9 (0.7141), but the AUC for TIMP-
1 (0.8320) was lower than IL-6 and higher than for CRP
[24, 25].
According to our knowledge, the present study is the
ﬁrst to compare the diagnostic criteria of IL-6 and CRP
with classic tumor markers, CEA and CA 19-9 in the sera
of GC patients. The percentage of increased concentrations
and the most important diagnostic criterion, area under
ROC curve, was the highest for IL-6 among biomarkers
tested (CRP, CEA and CA 19-9). In addition, we assessed
the serum IL-6, CRP and classic tumor markers concen-
trations in GC patients in relation to clinicopathological
features of tumor. We found that serum levels of all the
proteins were signiﬁcantly higher in GC patients than in
healthy subjects. Moreover, concentrations of IL-6, CEA
and CA 19-9 correlated with nodal metastasis, whereas CRP
with tumor stage, tumor size, presence of nodal and distant
metastases. Neither the proinﬂammatory proteins, IL-6 and
CRP nor tumor markers were found to be independent
prognostic factors for patients’ survival. In conclusion, our
ﬁndings suggest higher usefulness of serum IL-6 and CRP
than classic tumor markers, CEA and CA 19-9 in the
diagnosis of GC. However, general inﬂammatory state is
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123common to other epithelial tumors, such as pancreatic [28]
or colorectal cancer [17], where the concentrations of IL-6
and CRP increased in the line with the progress of tumor
disease. Therefore, further investigations are necessary.
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